Trials / Completed
CompletedNCT01846143
Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies
Evaluation of the Safety and Immunogenicity of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies (Mel59)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Craig L Slingluff, Jr · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn what effects (good and bad) experimental phosphopeptide vaccines plus a tetanus peptide and other substances called polyICLC and Montanide ISA-51 have on people with melanoma. The investigators will also look at whether the experimental reagents cause any changes in the immune system.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | pBCAR3-phosphopeptide | |
| BIOLOGICAL | pIRS2-phosphopeptide | |
| BIOLOGICAL | 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide) |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2015-06-01
- Completion
- 2015-11-01
- First posted
- 2013-05-03
- Last updated
- 2016-08-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01846143. Inclusion in this directory is not an endorsement.